<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2023-444</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-7988</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATION</subject></subj-group></article-categories><title-group><article-title>Эффективное лечение рецидива меланомы кожи с использованием иммунотерапии</article-title><trans-title-group xml:lang="en"><trans-title>Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3326-4961</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Когония</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kogoniya</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Когония Лали Михайловна - д.м.н., профессор, профессор кафедры онкологии и торакальной хирургии.</p><p>129110, Москва, ул. Щепкина, д. 61/2, корп. 1</p></bio><bio xml:lang="en"><p>Lali M. Kogoniya - Dr. Sci. (Med.), Professor, Professor of the Department of Oncology and Thoracic Surgery, Moscow Regional Research Clinical Institute named after M.F. Vladimirsky.</p><p>61/2, Bldg. 1, Schepkin St., Moscow, 129110</p></bio><email xlink:type="simple">lali51@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2028-566X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркарова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Markarova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маркарова Екатерина Васильевна - к.м.н., врач-онколог хирургического отделения, доцент кафедры онкологии и торакальной хирургии факультета усовершенствования врачей.</p><p>129110, Москва, ул. Щепкина, д. 61/2, корп. 1</p></bio><bio xml:lang="en"><p>Ekaterina V. Markarova - Cand. Sci. (Med.), Oncologist of the Surgical Department, Associate Professor of the Department of Oncology and Thoracic Surgery, Faculty of Advanced Training for Physicians, Moscow Regional Research Clinical Institute named after M.F. Vladimirsky.</p><p>61/2, Bldg. 1, Schepkin St., Moscow, 129110</p></bio><email xlink:type="simple">katemarkarova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research Clinical Institute named after M.F. Vladimirsky</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>01</month><year>2024</year></pub-date><volume>0</volume><issue>22</issue><fpage>196</fpage><lpage>200</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Когония Л.М., Маркарова Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Когония Л.М., Маркарова Е.В.</copyright-holder><copyright-holder xml:lang="en">Kogoniya L.M., Markarova E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/7988">https://www.med-sovet.pro/jour/article/view/7988</self-uri><abstract><p>В последние два десятилетия медицинское сообщество во всем мире является не только свидетелем, но и активным участником глобальной трансформации здравоохранения, происходящей на фоне стремительного развития современных биомедицинских технологий. Безусловно, в рамках данных преобразований можно выделить несколько достаточно самостоятельных направлений, однако большинство из них так или иначе могут быть объединены понятием «персонализированная медицина», которое является объектом дискуссий среди врачей всех специальностей, что подчеркивает его несомненную актуальность. Одним из ярких подтверждений этому является стремительный рост числа обзорных публикаций, посвященных рассмотрению вопросов персонализированного подхода в медицине. На примере одной из самых непредсказуемых опухолей – меланомы кожи – в последние годы были получены выразительные данные, свидетельствующие об эффективности индивидуальных подходов, персонификации лечения в результате использования своевременных, генно-молекулярных исследований. Несмотря на то что в большинстве случаев меланома локализуется на коже и при определенной степени онкологической настороженности может быть выявлена на ранних стадиях, статистика свидетельствует о неутешительных фактах запущенности заболевания. За последние 40 лет заболеваемость возросла на 300%. Возможности таргетной и иммунной терапии в лечении меланомы у пациентов с распространенной и нерезектабельной стадией заболевания позволяют длительно эффективно контролировать заболевание и его симптомы.</p></abstract><trans-abstract xml:lang="en"><p>Over the past two decades, the medical community around the world has been not only a witness, but an active participant in the global transformation of healthcare taking place against the backdrop of the rapid development of modern biomedical technologies. Of course, within the framework of these transformations, several quite independent directions can be distinguished. However, most of them, one way or another, can be united by the concept of “personalized medicine”, which is the subject of discussion among doctors of all specialties, which emphasizes its undoubted relevance. One of the clearest confirmations of this is the rapid growth in the number of review publications devoted to the consideration of issues of a personalized approach in medicine. Using the example of one of the most unpredictable tumors – skin melanoma – in recent years, expressive data have been obtained indicating the effectiveness of individual approaches, personalization of treatment as a result of the use of timely, gene-molecular studies. Despite the fact that in most cases melanoma is localized on the skin and, with a certain degree of oncological alertness, can be detected in the early stages, statistics indicate disappointing facts about the advanced state of the disease. Over the past 40 years, the incidence has increased by 300%. The possibilities of targeted and immunotherapy in the treatment of melanoma in patients with an advanced and unresectable stage of the disease allow long-term effective control of the disease and its symptoms.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>злокачественные новообразования</kwd><kwd>меланома</kwd><kwd>заболеваемость</kwd><kwd>химиотерапия меланомы кожи</kwd><kwd>иммунотерапия</kwd><kwd>пембролизумаб</kwd><kwd>индивидуальный подход</kwd><kwd>побочные явления</kwd></kwd-group><kwd-group xml:lang="en"><kwd>malignant neoplasms</kwd><kwd>melanoma</kwd><kwd>morbidity</kwd><kwd>chemotherapy for cutaneous melanoma</kwd><kwd>immunotherapy</kwd><kwd>pembrolizumab</kwd><kwd>individual approach</kwd><kwd>side effects</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293. https://doi.org/10.1056/NEJMoa1310669.</mixed-citation><mixed-citation xml:lang="en">Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293. https://doi.org/10.1056/NEJMoa1310669.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rajkumar S, Watson IR. Molecular characterization of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016;115(2):145–155. https://doi.org/10.1038/bjc.2016.195.</mixed-citation><mixed-citation xml:lang="en">Rajkumar S, Watson IR. Molecular characterization of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016;115(2):145–155. https://doi.org/10.1038/bjc.2016.195.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кушлинский НЕ, Мазуренко НН, Немцова МВ (ред.) Молекулярно­генетические маркеры опухолей. М.: Издательство РАМН; 2016. С. 85–128. Режим доступа: https://istina.fnkcrr.ru/collections/495536185/.</mixed-citation><mixed-citation xml:lang="en">Кушлинский НЕ, Мазуренко НН, Немцова МВ (ред.) Молекулярно­генетические маркеры опухолей. М.: Издательство РАМН; 2016. С. 85–128. Режим доступа: https://istina.fnkcrr.ru/collections/495536185/.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718–1729. https://doi.org/10.1016/S0140-6736(22)00562-1.</mixed-citation><mixed-citation xml:lang="en">Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718–1729. https://doi.org/10.1016/S0140-6736(22)00562-1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T-G et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–197. https://doi.org/10.1200/JCO.22.01763.</mixed-citation><mixed-citation xml:lang="en">Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T-G et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–197. https://doi.org/10.1200/JCO.22.01763.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ascierto PA, Mandala M, Ferrucci PF, Rutkowski P, Guidoboni M., Arance Fernandez AM et al. LBA40 SECOMBIT: The best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (encorafenib/binimetinib) in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Ann Oncol. 2021;32(5):S1316–S1317. https://doi.org/10.1016/j.annonc.2021.08.2118.</mixed-citation><mixed-citation xml:lang="en">Ascierto PA, Mandala M, Ferrucci PF, Rutkowski P, Guidoboni M., Arance Fernandez AM et al. LBA40 SECOMBIT: The best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (encorafenib/binimetinib) in patients with BRAF mutated metastatic melanoma: A phase II randomized study. Ann Oncol. 2021;32(5):S1316–S1317. https://doi.org/10.1016/j.annonc.2021.08.2118.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–137. https://doi.org/10.1200/JCO.21.02229.</mixed-citation><mixed-citation xml:lang="en">Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–137. https://doi.org/10.1200/JCO.21.02229.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Gutierrez EC et al. Relatlimab plus nivolumab versus nivolumab in first-line advanced melanoma. N Engl J Med. 2022;386:24–34. https://doi.org/10.1056/NEJMoa2109970.</mixed-citation><mixed-citation xml:lang="en">Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Gutierrez EC et al. Relatlimab plus nivolumab versus nivolumab in first-line advanced melanoma. N Engl J Med. 2022;386:24–34. https://doi.org/10.1056/NEJMoa2109970.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Строяковский ДЛ, Абрамов МЕ, Демидов ЛВ, Жукова НВ, Новик АВ, Орлова КВ и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли. 2021;11(3s2-1):244–263. https://doi.org/10.18027/2224-5057-2021-11-3s2-16.</mixed-citation><mixed-citation xml:lang="en">Stroyakovsky DL, Abramov ME, Demidov LV, Zhukova NV, Novik AV, Orlovа KV et al. Practical recommendations for the drug treatment of skin melanoma. Malignant Tumors. 2021;11(3s2-1):244–263. https://doi.org/10.18027/2224-5057-2021-11-3s2-16.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Larkin J, Sarnaik A, Chesney J, Khushalani N, Kirkwood J, Weber J et al. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. J Clin Oncol. 2021;39(15 Suppl.):9505. https://doi.org/10.1200/JCO.2021.39.15_suppl.9505.</mixed-citation><mixed-citation xml:lang="en">Larkin J, Sarnaik A, Chesney J, Khushalani N, Kirkwood J, Weber J et al. Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. J Clin Oncol. 2021;39(15 Suppl.):9505. https://doi.org/10.1200/JCO.2021.39.15_suppl.9505.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nathan P, Hassel JC, Rutkowski P, Baurain J, Butler M, Schlaak M et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196–1206. https://doi.org/10.1056/NEJMoa2103485.</mixed-citation><mixed-citation xml:lang="en">Nathan P, Hassel JC, Rutkowski P, Baurain J, Butler M, Schlaak M et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196–1206. https://doi.org/10.1056/NEJMoa2103485.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889–1894. https://doi.org/10.1200/JCO.2014.56.2736.</mixed-citation><mixed-citation xml:lang="en">Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889–1894. https://doi.org/10.1200/JCO.2014.56.2736.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol. 2016;34(15 Suppl.):9503. https://doi.org/10.1200/JCO.2016.34.15_suppl.9503.</mixed-citation><mixed-citation xml:lang="en">Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol. 2016;34(15 Suppl.):9503. https://doi.org/10.1200/JCO.2016.34.15_suppl.9503.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): mumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2.</mixed-citation><mixed-citation xml:lang="en">Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): mumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol. 2016;27(6 Suppl.):vi379–vi400. https://doi.org/10.1093/annonc/mdw379.02.</mixed-citation><mixed-citation xml:lang="en">Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol. 2016;27(6 Suppl.):vi379–vi400. https://doi.org/10.1093/annonc/mdw379.02.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.</mixed-citation><mixed-citation xml:lang="en">Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. Lancet. 2017;390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X.</mixed-citation><mixed-citation xml:lang="en">Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. Lancet. 2017;390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
